IN2015DN01163A - - Google Patents

Info

Publication number
IN2015DN01163A
IN2015DN01163A IN1163DEN2015A IN2015DN01163A IN 2015DN01163 A IN2015DN01163 A IN 2015DN01163A IN 1163DEN2015 A IN1163DEN2015 A IN 1163DEN2015A IN 2015DN01163 A IN2015DN01163 A IN 2015DN01163A
Authority
IN
India
Prior art keywords
syndrome
mediated
disorder
transportation
disease
Prior art date
Application number
Other languages
English (en)
Inventor
Jan Jiricek
Ravinder Reddy Kondreddi
Paul William Smith
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IN2015DN01163A publication Critical patent/IN2015DN01163A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/4045Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/06Antibacterial agents for tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/056Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IN1163DEN2015 2012-09-07 2015-02-12 IN2015DN01163A (enrdf_load_html_response)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261698033P 2012-09-07 2012-09-07
PCT/IB2013/058318 WO2014037900A1 (en) 2012-09-07 2013-09-05 Indole carboxamide derivatives and uses thereof

Publications (1)

Publication Number Publication Date
IN2015DN01163A true IN2015DN01163A (enrdf_load_html_response) 2015-06-26

Family

ID=49585451

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1163DEN2015 IN2015DN01163A (enrdf_load_html_response) 2012-09-07 2015-02-12

Country Status (11)

Country Link
US (3) US9447039B2 (enrdf_load_html_response)
EP (1) EP2892880B1 (enrdf_load_html_response)
JP (1) JP6223452B2 (enrdf_load_html_response)
KR (1) KR20150048759A (enrdf_load_html_response)
CN (1) CN104603106B (enrdf_load_html_response)
BR (1) BR112015004666B1 (enrdf_load_html_response)
CA (1) CA2881351A1 (enrdf_load_html_response)
EA (1) EA028093B1 (enrdf_load_html_response)
ES (1) ES2660210T3 (enrdf_load_html_response)
IN (1) IN2015DN01163A (enrdf_load_html_response)
WO (1) WO2014037900A1 (enrdf_load_html_response)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3125883B1 (en) * 2014-04-04 2020-08-12 Iomet Pharma Ltd. Indole derivatives for use in medicine
US20170044100A1 (en) * 2014-04-22 2017-02-16 The Johns Hopkins University Inhibitors of drug-resistant mycobacterium tuberculosis
ES2809974T3 (es) * 2014-10-24 2021-03-08 Bristol Myers Squibb Co Compuestos de indol carboxamida útiles como inhibidores de cinasas
CN107298650B (zh) * 2016-04-15 2022-11-15 浙江中科创越药业有限公司 杂环羧酸酰胺配体及其在铜催化芳基卤代物偶联反应中的用途
CN106085868B (zh) * 2016-06-15 2019-07-12 中国医学科学院医药生物技术研究所 一株曲霉菌及其应用
US10383848B2 (en) * 2016-08-04 2019-08-20 Creighton University Indole-based therapeutics
US10858319B2 (en) 2016-10-03 2020-12-08 Iomet Pharma Ltd. Indole derivatives for use in medicine
US11938114B2 (en) 2017-03-10 2024-03-26 Rutgers, The State University Of New Jersey Bacterial efflux pump inhibitors
WO2018165611A1 (en) 2017-03-10 2018-09-13 Rutgers, The State University Of New Jersey Indole derivatives as efflux pump inhibitors
US11180459B2 (en) 2017-03-10 2021-11-23 Rutgers, The State University Of New Jersey Bacterial efflux pump inhibitors
JP7281822B2 (ja) * 2017-05-26 2023-05-26 ラトガーズ、ザ ステイト ユニバーシティ オブ ニュージャージー 細菌の排出ポンプ阻害剤
WO2019005841A1 (en) * 2017-06-26 2019-01-03 Rutgers, The State University Of New Jersey THERAPEUTIC COMPOUNDS AND METHODS FOR TREATING INFECTION
EP3793976A4 (en) * 2018-05-17 2022-04-20 Council of Scientific & Industrial Research Indole compounds, process for the preparation and use thereof
KR102219563B1 (ko) * 2019-02-15 2021-02-24 에스티팜 주식회사 페나진 유도체 제조를 위한 중간체 및 그의 제조방법
CN110577483B (zh) * 2019-09-26 2020-05-12 海南医学院 一种3,3-二取代-2-吲哚酮的绿色合成方法
WO2021062319A1 (en) * 2019-09-26 2021-04-01 The Global Alliance For Tb Drug Development, Inc. Indole carboxamide compounds and use thereof for the treatment of mycobacterial infections
KR20220070489A (ko) * 2019-09-26 2022-05-31 더 글로벌 얼라이언스 포 티비 드러그 디벨롭먼트, 잉크. 티아졸 카복사미드 화합물 및 미코박테리아 감염의 치료를 위한 이의 용도
KR20220070491A (ko) * 2019-09-26 2022-05-31 더 글로벌 얼라이언스 포 티비 드러그 디벨롭먼트, 잉크. 미코박테리아 감염의 치료를 위한 아자인돌 카복사미드 화합물
RU2767542C1 (ru) * 2021-05-24 2022-03-17 Федеральное государственное автономное образовательное учреждение высшего образования "Пермский государственный национальный исследовательский университет" (ПГНИУ) Противотуберкулезное средство на основе 4-((гет)ароил)-3- гидрокси-1-(2-гидроксифенил)-5-(фенилтио)-1,5-дигидро-2Н-пиррол-2-онов
CN115583908B (zh) * 2021-07-05 2024-08-06 西北农林科技大学 一种吲哚甲酰胺类化合物及其制备方法和用途
WO2023287704A1 (en) * 2021-07-12 2023-01-19 Nido Biosciences, Inc. Bicyclic compounds as androgen receptor modulators
US20240254114A1 (en) * 2022-12-02 2024-08-01 Merck Sharp & Dohme Llc Preparation of fused azole derivatives as novel diacylglyceride 0-acyltransferase 2 inhibitors
CN118724763B (zh) * 2024-09-02 2024-12-06 辽宁龙田化工科技有限公司 一种4-甲基苯磺酰氯合成方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US883049A (en) * 1907-09-12 1908-03-24 John W Piver Tongue-and-groove joint for flooring.
FR2705095B1 (fr) * 1993-05-12 1995-06-23 Adir Nouveaux indoles substitués, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
HU227197B1 (en) * 2000-10-24 2010-10-28 Richter Gedeon Nyrt Nmda receptor antagonist carboxylic acid amide derivatives and pharmaceutical compositions containing them
US7365205B2 (en) 2001-06-20 2008-04-29 Daiichi Sankyo Company, Limited Diamine derivatives
CA2464214C (en) 2001-10-22 2011-02-08 The Research Foundation Of State University Of New York Protein kinase and phosphatase inhibitors, methods for designing them, and methods of using them
IL161992A0 (en) 2001-12-04 2005-11-20 Hoffmann La Roche Substituted 2-amino-cycloalkanecarboxamides and t heir use as cysteine protease inhibitors
US6759428B2 (en) 2001-12-04 2004-07-06 Roche Palo Alto Llc Indole nitriles
AU2003227360A1 (en) * 2002-04-25 2003-11-10 Yamanouchi Pharmaceutical Co., Ltd. Novel amide derivatives or salts thereof
CA2514733A1 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
GB0428173D0 (en) 2004-12-23 2005-01-26 Astrazeneca Ab Compounds
CA2617123C (en) * 2005-08-12 2015-05-26 United States Government As Represented By The Secretary Of The United States Army And The U.S. Army Medical Research & Materiel Command Broad spectrum antibacterial compounds
CA2647596C (en) 2006-04-04 2012-06-12 Fibrogen, Inc. Pyrrolo- and thiazolo-pyridine compounds as hif modulators
WO2009063495A2 (en) 2007-09-20 2009-05-22 Cadila Healthcare Limited Substituted indole and its derivatives as cannabinoid modulators
PE20110819A1 (es) 2008-12-19 2011-11-02 Bristol Myers Squibb Co Compuestos de carbazol carboxamida utiles como inhibidores de cinasa
JP5854841B2 (ja) 2009-02-27 2016-02-09 シガ・テクノロジーズ・インコーポレーテッド デングウイルス感染を治療及び予防するためのチエノピリジン誘導体類
AU2010278730A1 (en) 2009-07-31 2012-03-01 Biocryst Pharmaceuticals, Inc. Pyrrolo [1, 2-b] pyridazine derivatives as janus kinase inhibitors
CA2781888C (en) 2009-12-11 2019-06-18 Nono Inc. Agents and methods for treating ischemic and other diseases
JP2012107001A (ja) * 2010-10-22 2012-06-07 Shionogi & Co Ltd インドールアミド化合物を含有する医薬
US9200046B2 (en) * 2011-06-29 2015-12-01 Cornell University Reporter system for high throughput screening of compounds and uses thereof

Also Published As

Publication number Publication date
WO2014037900A1 (en) 2014-03-13
BR112015004666A2 (pt) 2017-07-04
CN104603106B (zh) 2017-05-10
EP2892880B1 (en) 2017-11-22
US9447039B2 (en) 2016-09-20
AU2013311235A1 (en) 2015-02-26
AU2013311235B2 (en) 2016-03-24
ES2660210T3 (es) 2018-03-21
EA028093B1 (ru) 2017-10-31
JP6223452B2 (ja) 2017-11-01
EA201590504A1 (ru) 2015-07-30
US20160355477A1 (en) 2016-12-08
CA2881351A1 (en) 2014-03-13
KR20150048759A (ko) 2015-05-07
JP2015527388A (ja) 2015-09-17
CN104603106A (zh) 2015-05-06
US20210032202A1 (en) 2021-02-04
US20150175539A1 (en) 2015-06-25
EP2892880A1 (en) 2015-07-15
BR112015004666B1 (pt) 2022-04-26

Similar Documents

Publication Publication Date Title
IN2015DN01163A (enrdf_load_html_response)
EA201591527A1 (ru) Новые производные пиридина
PH12015501083B1 (en) Novel pyridine derivatives
MX2015015412A (es) Compuestos novedosos y composiciones farmaceuticas de los mismos para el tratamiento de fibrosis quistica.
MX350539B (es) Compuestos de enediino, conjugados de los mismos y sus usos y metodos.
MY176814A (en) Compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis
MY182328A (en) Pyridine-2-amides useful as cb2 agonists
PH12015501933A1 (en) Novel pyridine derivatives
MY179412A (en) Pyridine-2-amides useful as cb2 agonists
PH12015501843A1 (en) Novel pyrazol derivatives
EA201291317A1 (ru) Тетрагидропиридопиримидиновые производные
MX2014004920A (es) Nuevos derivados de pirazina.
PH12015501038A1 (en) Inhibitors of iap
MX2014008918A (es) Nuevos derivados de pirrolidina.
MX2015016766A (es) Nuevos derivados de tetrazolona.
PH12015500262A1 (en) Novel pyridine derivatives
MX351093B (es) Nuevos derivados de azetidina.
IN2015DN02513A (enrdf_load_html_response)